In 1998, Tatemoto et al. first isolated apelin from bovine stomach extracts. Apelin is an endogenous peptide ligand for the orphan G-protein-coupled angiotensin receptor-like protein J (APJ) receptor. It is widely distributed in various organs such as the lung, kidney, liver, heart, gastrointestinal tract, and adipose tissue, etc. And it was identified as a novel adipocytokine in 2005.
Apelin has many subtypes, including Apelin-36, Apelin-31, Apelin-28, Apelin-19, Apelin-13, and Apelin-12, etc., among which Apelin-36 is the main form of endogenous Apelin. And it exerts extensive functions in the human body, including the control of blood pressure and blood flow, the stimulation of cardiac contractility, the regulation of water and food intake, adipocyte differentiation, the involvement in glucose uptake and participation in the control of glucose blood levels glycemia.
Apelin signaling pathway refers to the way by which apelin binds to its cognate receptor APJ, thereby mediating the occurrence of multiple signaling pathways that involve in many cellular processes.
In the apelin signaling pathway, apelin is activated by its cognate APJ receptor, triggering a diversity of physiological effects such as vasoconstriction and dilation, the control of blood pressure and blood flow, strengthening of cardiac contractility, angiogenesis, and modulation of energy metabolism and fluid homeostasis.
Apelin exerts its physiologic and pathophysiologic functions through the interaction with its receptor APJ, in the autocrine or paracrine pathway.
Apelin and APJ are found to be highly expressed in various peripheral tissues, especially in the blood vessels, indicating that apelin/APJ plays an important role in angiogenesis and vascular formation. Apelin acts on and activates the APJ receptor. Activated APJ combines with Gi protein and PKC, phosphorylation of p70 S6 kinase through the extracellular signal-regulated kinase (ERK) pathway. Apelin/APJ signaling also activates the phosphatidylinositol 3-kinase (PI3K)-Akt pathway, facilitating endothelial cell migration. Active Akt stimulates the phosphorylation of p70 S6 kinase. Both cell events ultimately promote the proliferation of vascular smooth muscle cells. Liu C et al. also confirmed that this signaling pathway inhibits the apoptosis of vascular smooth muscle cells.
The apelin/APJ pathway mediates the opposite effects to the renin-angiotensin system (RAS) in many physiologic and pathophysiologic conditions. Angiotensin II elevates vascular tone and raises blood pressure, whereas apelin acts as a vasodilator and lowers blood pressure. Many studies have demonstrated that intravenous injection of exogenous apelin can cause decreased systolic and diastolic blood pressure. Apelin binds to and activates APJ, stimulating Akt to activate phosphorylation of endothelial nitric oxide synthase (eNOS). The phosphorylation of eNO promotes the release of NO by endothelial cells. NO increases cGMP by activating ornithylacine cyclase in smooth muscle, which further relaxes vascular smooth muscle and lowers blood pressure, leading to vasodilatation.
The apelin signaling pathway also inhibits adipogenesis through the MAPK pathway and suppresses basal lipolysis through AMP-activated protein kinase-dependent enhancement of perilipin expression.
Apelin is involved in the pathogenesis of many diseases such as heart failure, coronary heart disease, diabetes, lung diseases, and cancer.
Studies have shown that apelin levels increase in the early stage of heart failure but disease in the late stage. In patients with type II diabetes, plasma apelin concentrations are increased. In the study of osteoarthritis (OA), apelin was found in the synovial fluid of osteoarthritis. And its concentration was positively correlated with the severity of OA, suggesting that apelin played a certain role in the occurrence or development of OA. It provides a new perspective on OA pathology.
Apelin has been reported to be widely expressed in endothelial cells of tumors of different origins. And apelin has been identified as a tumor endothelial-specific gene through the gene expression profiles comparison between tumor and normal endothelium.
|NOS1||NOS1 Antibody||NOS1 Protein||NOS1 cDNA||NOS1 ELISA Kit|
|NOS2||NOS2 Antibody||NOS2 Protein||NOS2 cDNA||NOS2 ELISA Kit|
|NOS3||NOS3 Antibody||NOS3 Protein||NOS3 cDNA||NOS3 ELISA Kit|
|NOTCH3||NOTCH3 Antibody||NOTCH3 Protein||NOTCH3 cDNA||NOTCH3 ELISA Kit|
|NRAS||NRAS Antibody||NRAS Protein||NRAS cDNA||NRAS ELISA Kit|
|NRF1||NRF1 Antibody||NRF1 Protein||NRF1 cDNA||NRF1 ELISA Kit|
|PDE3B||PDE3B Antibody||PDE3B Protein||PDE3B cDNA||PDE3B ELISA Kit|
|PIK3C3||PIK3C3 Antibody||PIK3C3 Protein||PIK3C3 cDNA||PIK3C3 ELISA Kit|
|PIK3CG||PIK3CG Antibody||PIK3CG Protein||PIK3CG cDNA||PIK3CG ELISA Kit|
|PIK3R4||PIK3R4 Antibody||PIK3R4 Protein||PIK3R4 cDNA||PIK3R4 ELISA Kit|
|PIK3R5||PIK3R5 Antibody||PIK3R5 Protein||PIK3R5 cDNA||PIK3R5 ELISA Kit|
|PIK3R6||PIK3R6 Antibody||PIK3R6 Protein||PIK3R6 cDNA||PIK3R6 ELISA Kit|
|PLAT||PLAT Antibody||PLAT Protein||PLAT cDNA||PLAT ELISA Kit|
|PLCB1||PLCB1 Antibody||PLCB1 Protein||PLCB1 cDNA||PLCB1 ELISA Kit|
|PLCB2||PLCB2 Antibody||PLCB2 Protein||PLCB2 cDNA||PLCB2 ELISA Kit|
|PLCB3||PLCB3 Antibody||PLCB3 Protein||PLCB3 cDNA||PLCB3 ELISA Kit|
|PLCB4||PLCB4 Antibody||PLCB4 Protein||PLCB4 cDNA||PLCB4 ELISA Kit|
|PLIN1||PLIN1 Antibody||PLIN1 Protein||PLIN1 cDNA||PLIN1 ELISA Kit|
|PPARGC1A||PPARGC1A Antibody||PPARGC1A Protein||PPARGC1A cDNA||PPARGC1A ELISA Kit|
|PRKAA1||PRKAA1 Antibody||PRKAA1 Protein||PRKAA1 cDNA||PRKAA1 ELISA Kit|